Core Viewpoint - The company, Yaoshi Bang, is leveraging digital transformation to enhance its position in the pharmaceutical industry, achieving significant growth in revenue and profit in the first half of 2025, indicating a successful adaptation to market changes and a strong strategic direction [2][6]. Group 1: Financial Performance - In the first half of 2025, Yaoshi Bang reported a revenue of 9.843 billion yuan, a year-on-year increase of 11.7%, and a net profit of 78 million yuan, which represents a more than threefold increase compared to the previous year [2][6]. - The gross profit margin improved from 10% to 11.2%, and the net profit increased by 258% year-on-year, with operating cash flow reaching 257 million yuan [6]. Group 2: Market Position and Strategy - Yaoshi Bang has transformed from a startup addressing the "difficulties in finding medicine" for grassroots pharmacies to a comprehensive digital service platform covering 98.9% of counties and 91.2% of townships in China [2][3]. - The company focuses on empowering grassroots markets by connecting over 3,000 pharmaceutical wholesalers and aggregating demands from more than 400,000 grassroots pharmacies and clinics [3][4]. Group 3: Product and Service Innovation - In 2024, Yaoshi Bang launched its own brand products, such as Huo Xiang Zheng Qi Oral Liquid, achieving significant sales growth, with the proprietary brand business revenue reaching 1.08 billion yuan in the first half of 2025, a year-on-year increase of 115.6% [5]. - The company has established over 20 digital strategic centers across the country, enhancing its supply chain efficiency and achieving a same-city delivery rate of 70% for orders [5][6]. Group 4: Industry Impact and Future Outlook - Yaoshi Bang is positioned as a "value creator" in the pharmaceutical industry, leading the transformation from a focus on scale to profitability, and expanding its coverage of grassroots medical institutions by 133.7% over three years [6][8]. - The company is actively adapting to regulatory changes and has implemented a drug traceability system to help reduce compliance costs for grassroots terminals [7][9].

Core Viewpoint - The company, Yaoshi Bang (09885), has demonstrated significant growth in its financial performance for the first half of 2025, achieving a notable increase in revenue and net profit despite a challenging pharmaceutical market environment [1][2]. Financial Performance - In the first half of 2025, the company reported a revenue of 9.843 billion yuan, representing a year-on-year growth of 11.7% [1]. - The gross profit margin improved from 10% to 11.2% [1]. - The net profit attributable to shareholders reached 78.11 million yuan, showing an increase of over 300% compared to the same period last year [1]. - Operating cash flow remained positive with a net inflow of 2.57 billion yuan, and cash and cash equivalents totaled 3.551 billion yuan [1]. Business Strategy - The company has maintained steady growth through a "platform + self-operated" dual-driven model, focusing on three strategic areas: expansion of self-owned brands, enhancement of supply chain efficiency, and development of grassroots medical services [1]. - The continuous expansion of self-owned brand business has further improved the company's supply and operational capabilities, leading to sustained growth in high-margin business [2]. Product Performance - The transaction scale of self-owned brands reached 852 million yuan, marking a year-on-year increase of approximately 473.4% [2]. - The strategic product, Huo Xiang Zheng Qi Oral Liquid, contributed 40% of sales from grassroots medical institution clients [2]. - Another key product, Le Yao Shi Chang Yan Ning Oral Liquid, has covered over 30,000 single pharmacies and grassroots medical institutions within two months [2].

Core Insights - The company reported a significant increase in revenue and profit for the first half of 2025, achieving a revenue of 9.843 billion RMB, a year-on-year growth of 11.7% [1] - The gross profit margin improved from 10% to 11.2%, indicating enhanced profitability [1] - Net profit reached 78.11 million RMB, representing a more than threefold increase compared to the same period last year [1] - Operating cash flow remained positive at 2.57 billion RMB, with cash and cash equivalents totaling 3.551 billion RMB [1] Business Strategy - The company maintained robust growth through a "platform + self-operated" dual-drive model, focusing on digital infrastructure, brand expansion, supply chain efficiency, and grassroots medical layout [1] - The continuous expansion of self-owned brand business has enhanced supply and operational capabilities, leading to sustained growth in high-margin business [2] - The transaction scale of self-owned brands reached 852 million RMB, with a year-on-year growth of approximately 473.4% [2] - Key products such as Huoxiang Zhengqi Oral Liquid contributed 40% of sales from grassroots medical institutions, while another product, Leyaozhi Changyanning Oral Liquid, covered over 30,000 pharmacies and grassroots medical institutions within two months [2]

Core Viewpoint - Multiple companies, including Tencent Holdings and China Hongqiao, conducted share buybacks on August 21, 2025, with Tencent leading in both volume and monetary value [1][2]. Group 1: Company Buyback Details - Tencent Holdings (00700) repurchased 928,000 shares for a total of 551 million, with a year-to-date total of 41.195 million shares, representing 0.448% of its total share capital [2]. - China Hongqiao (01378) bought back 1,469,500 shares for 35.1603 million, accumulating 54.111 million shares year-to-date, which is 0.580% of its total share capital [2]. - Techtronic Industries (00669) repurchased 250,000 shares for 25.0849 million, with a total of 1 million shares repurchased this year, accounting for 0.055% of its total share capital [2]. - Hang Seng Bank (00011) bought back 200,000 shares for 22.4935 million, totaling 3 million shares year-to-date, which is 0.159% of its total share capital [2]. - Beisen Holdings (09669) repurchased 450,000 shares for 3.5653 million, with a total of 7.345 million shares repurchased this year, representing 1.046% of its total share capital [2]. - Yuan Zheng Technology (02488) repurchased 174,000 shares for 1.9676 million, totaling 236,450 shares year-to-date, which is 1.464% of its total share capital [2]. - Corning Hospital (02120) bought back 120,900 shares for 1.2775 million, with a total of 463,100 shares repurchased this year, accounting for 0.640% of its total share capital [2]. - Guichuang Tongqiao-B (02190) repurchased 50,000 shares for 1.1835 million, totaling 160,250 shares year-to-date, which is 0.490% of its total share capital [2]. - Yaoshi Bang (09885) bought back 100,000 shares for 1.0231 million, with a total of 202,820 shares repurchased this year, representing 0.297% of its total share capital [2]. - Fuzhikang Group (02038) repurchased 70,000 shares for 1.0131 million, totaling 367,180 shares year-to-date, which is 0.466% of its total share capital [2]. - Miniso (09896) bought back 16,000 shares for 607,000, with a total of 368,080 shares repurchased this year, accounting for 0.297% of its total share capital [2]. - Tsugami Machine Tool China (01651) repurchased 10,000 shares for 269,100, with a total of 10,000 shares repurchased this year, representing 0.003% of its total share capital [2]. - Sunrise Enterprises (00393) bought back 8,000 shares for 10,600, with a total of 544,000 shares repurchased this year, accounting for 0.036% of its total share capital [2]. - Tenfu (06868) repurchased 3,000 shares for 91,600, with a total of 359,000 shares repurchased this year, representing 0.033% of its total share capital [2]. - Qiancheng Chuangye (01945) bought back 3,600 shares for 46,960, with a total of 71,880 shares repurchased this year, accounting for 0.240% of its total share capital [2].

Core Viewpoint - The digital pharmaceutical platform Yaoshi Bang (9885.HK) has achieved impressive financial results in the first half of 2025, with revenue of 9.843 billion yuan, a year-on-year increase of 11.7%, and a net profit of 78.117 million yuan, marking a 258% increase compared to the same period in 2024, indicating a successful transition from "scale expansion" to "quality improvement" in its business model [1][4]. Financial Performance - In the first half of 2025, Yaoshi Bang's total revenue reached 9.843 billion yuan, with a year-on-year growth rate of 11.7%, significantly exceeding the industry average [4]. - The company's gross profit margin increased to 11.2%, driven by high-margin self-owned brands, contributing to a net profit of 78.117 million yuan, which represents a 258% year-on-year increase [4][5]. - As of June 30, 2025, the company had cash equivalents of 1.106 billion yuan, a year-on-year increase of 6.22%, and a net operating cash inflow of 257 million yuan, indicating a strong financial position [5]. Market Response - As of August 20, 2025, Yaoshi Bang's stock price had increased by 88.17% year-to-date, outperforming the Hang Seng Index and being included in the MSCI Global Small Cap Index, reflecting strong market recognition of its digital pharmaceutical distribution model [1][3]. Industry Context - The pharmaceutical retail industry is currently undergoing a deep adjustment phase, characterized by rising compliance costs and accelerated market clearing, which creates structural opportunities for leading companies [8]. - Future competitiveness in the industry will depend on the depth of professional services and supply chain efficiency rather than mere store expansion or price wars [8]. Strategic Focus - Yaoshi Bang is focusing on three strategic pillars: enhancing supply chain efficiency, expanding self-owned brand business, and developing grassroots medical layouts, which are essential for addressing the urgent transformation needs of the pharmaceutical retail sector [9]. - The integration of AI and SaaS tools is a key strategy for optimizing supply chain algorithms and upgrading pharmacy operations [9]. Growth Potential - The self-owned brand business has shown significant growth, with transaction volume reaching 85.2 billion yuan in the first half of 2025, a 473% year-on-year increase [9]. - The company has developed a comprehensive solution for grassroots medical services, enhancing operational efficiency and capabilities of grassroots medical institutions [9]. Valuation Outlook - According to research from Xinda Securities, Yaoshi Bang is expected to enter a profit harvest phase, with a projected compound annual growth rate (CAGR) of 164% for net profit from 2024 to 2027 [10]. - The company's unique "platform + service + ecosystem" business model is expected to drive a significant revaluation, with target valuations ranging from 7.4 billion to 13.4 billion HKD [10].

Core Viewpoint - The company reported strong growth in its mid-2025 performance, with significant increases in revenue and net profit, driven by robust performance in its proprietary brand business and improved gross margin structure [1][2]. Revenue Structure - In H1 2025, the company's total revenue reached approximately 9.843 billion yuan, representing a year-on-year increase of 11.7% [1]. - Self-operated business revenue was 9.389 billion yuan, up 12.53% year-on-year, with the proprietary brand business transaction volume reaching 1.08 billion yuan, a remarkable increase of 115.6% [1]. - The self-owned brand transaction volume surged to 852 million yuan, reflecting a year-on-year growth of 473.4% [1]. - Platform business revenue was 436 million yuan, down 0.95% year-on-year, primarily due to a sluggish retail drug market affecting third-party sellers [2]. - Other income decreased to 17 million yuan, a decline of 40.56% year-on-year, mainly due to adjustments in the operational/service model for Guangpu Cloud Inspection [2]. Profitability - The adjusted net profit for H1 2025 was approximately 122 million yuan, up 33.2% year-on-year, while the net profit attributable to the parent company was about 78 million yuan, a significant increase of 258% [1]. - The adjusted net profit margin improved by approximately 0.2 percentage points to 1.2%, while the overall net profit margin increased by about 0.6 percentage points to 0.75% [2]. - The gross margin rose by approximately 1.22 percentage points to 11.22%, driven by the rapid growth of high-margin proprietary brand business [2]. User Engagement and Platform Development - The average monthly active buyers on the platform reached 453,000, a year-on-year increase of 6.5%, with average monthly paying buyers at 426,000, up 7.6% [3]. - The platform maintained a high payment rate of 94%, with each paying buyer averaging about 29.2 orders per month [3]. - The company is enhancing its platform and self-operated business while exploring high-growth sectors, such as the launch of the "Guangpu Xiaowu" grassroots smart medical solutions [3]. Future Outlook - Revenue projections for 2025-2027 are approximately 20.8 billion yuan, 23.5 billion yuan, and 26.7 billion yuan, with year-on-year growth rates of 16%, 13%, and 14% respectively [4]. - Expected net profits for the same period are 148 million yuan, 320 million yuan, and 549 million yuan, with respective year-on-year growth rates of 394%, 116%, and 72% [4].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 藥師幫股份有限公司 (於開曼群島註冊成立之有限公司) 呈交日期： 2025年8月21日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 09885 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行 ...

Core Viewpoint - The company, Yaoshi Bang (09885), has conducted a share buyback, indicating confidence in its future growth potential and commitment to shareholders [1] Group 1: Share Buyback Details - The company repurchased a total of 100,000 shares on August 21, 2025, under the 2025 share buyback authorization [1] - The total amount spent on the buyback was approximately 1.0231 million Hong Kong dollars, excluding commissions and other expenses [1] - The average repurchase price was 10.2311 Hong Kong dollars per share [1] Group 2: Insider Buying - Executive Director Chen Fei purchased a total of 50,000 shares in the open market on the same day [1] - The board believes that Chen Fei's increase in shareholding reflects his confidence in the company's prospects and growth potential [1] - This action also demonstrates his long-term commitment to the company [1]

Core Viewpoint - The company, Yaoshi Bang (09885), has repurchased a total of 100,000 shares on August 21, 2025, under its share buyback authorization for 2025, with a total expenditure of approximately HKD 1.0231 million, excluding commissions and other expenses, at an average repurchase price of HKD 10.2311 per share. The repurchased shares will be canceled in due course [1]. Summary by Relevant Sections - Share Buyback Details - The company repurchased 100,000 shares at an average price of HKD 10.2311 per share [1]. - The total amount spent on the buyback was approximately HKD 1.0231 million, excluding commissions and other expenses [1]. - The repurchased shares are set to be canceled [1]. - Insider Buying - Executive Director Chen Fei purchased a total of 50,000 shares in the open market on the same date [1]. - The board views Chen Fei's share purchase as a sign of confidence in the company's future and growth potential, reflecting his long-term commitment to the company [1].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責 任。 此公告乃藥師幫股份有限公司（「本公司」）自願向本公司股東（「股 東」）及本公司 潛 在 投 資 者 作 出。 股份回購 茲提述本公司日期為2025年5月7日、2025年5月9日、2025年5月12日、2025年5月 13日、2025年5月14日、2025年5月15日、2025年5月16日、2025年5月19日、2025年5 月21日、2025年5月22日、2025年5月23日、2025年5月26日、2025年5月27日、2025 年6月4日、2025年6月5日、2025年6月11日、2025年6月17日 及2025年6月23日的公 告（「該等公告」），內 容 有 關（其 中 包 括）其 股 份 回 購 計 劃。本 公 司 將 根 據 市 況 及 資 金 安 排，於 市 場 上 回 購 總 額 最 多1億 港 元 的 股 份。除 另 有 說 明 者 ...